Medical devices, healthcare technology and the business of care
PMA approval · P250011

ProVee System for BPH

Proverum, Ltd. · Decision date Dec 9, 2025

FDA DECISIONP250011

What did the FDA approve?

FDA records P250011 as an original PMA application. The recorded decision is approval, dated Dec 9, 2025.

FDA approval order statement

The ProVee System for BPH is intended for the treatment of obstructive lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH) in men with prostatic urethral lengths greater than or equal to 3.75 cm and prostatic volumes between 30 and 80 cc.
Regulatory pathway
Original PMA
Clinical specialty
Gastroenterology, Urology
Decision date
Dec 9, 2025

FDA source record

Regulatory record facts

Identifier
P250011
Regulatory pathway
Premarket approval application
Product code
MER
Decision code
APPR
Decision date
Dec 9, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: STENT, URETHRAL, PROSTATIC, PERMANENT OR SEMI-PERMANENT.

Product code
MER
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P250011 received

    Application receipt date recorded by FDA.

  2. P250011 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P250011. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250011

Product / regulatory recordCompanyPathwayDecision dateSource
Proverum, Ltd.PMA supplementSep 24, 2026FDA
Proverum, Ltd.PMA supplementNov 3, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Proverum, Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
2nd Floor Astor Hall, 4-8 Eden Quay, Dublin, D01N5W8

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records